- Baxter (BAX -0.5%) gets another indication for the hemophilia treatment FEIBA.
- The FDA has approved the drug for the prophylactic treatment of patients with hemophilia A or B who have developed inhibitors.
- "This additional indication ... is aimed at reducing the number of bleeds among this patient population," the company's president of BioScience says. (PR)
Baxter gets FDA nod for FEIBA as a prophylactic
Recommended For You
More Trending News
About BAX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
BAX | - | - |
Baxter International Inc. |